# Neurogenic Bladder in Children with Myelomeningocele

**Authors:** Aleksandar Sič, Borko Stojanović, Miroslav Đorđević

PMC · DOI: 10.3390/diseases13040117 · Diseases · 2025-04-17

## TL;DR

This review discusses the urological challenges in children with myelomeningocele and highlights the need for a multidisciplinary approach to improve bladder function and patient outcomes.

## Contribution

The paper provides a comprehensive overview of neurogenic bladder management in myelomeningocele, emphasizing multidisciplinary care and future research directions.

## Key findings

- Neurogenic bladder dysfunction in myelomeningocele requires a multidisciplinary approach for optimal management.
- Non-surgical interventions like CIC and oxybutynin are commonly used to manage complications.
- Surgical options such as botulinum toxin and reconstructive procedures can improve urological outcomes.

## Abstract

Myelomeningocele (MMC), a severe congenital anomaly resulting from neural tube closure defects, poses significant urological challenges necessitating specialized care. This review explores the intricate landscape of MMC within urological practice, advocating for a multidisciplinary approach to optimize patient outcomes. By surveying diverse treatment modalities, this review aims to offer insights into enhancing urological management strategies for MMC and guiding future research directions. At the heart of the conversation lies the pathophysiology of neurogenic bladder dysfunction in children with MMC, with a particular focus on the complexities of diagnosis and the various paradigms guiding urological management. Common complications such as recurrent urinary tract infections are examined alongside non-surgical interventions like intermittent catheterization (CIC) and pharmacotherapy, notably oxybutynin. Additionally, surgical options including botulinum toxin injection and reconstructive procedures are explored to enhance urological outcomes for affected children. By unpacking the complexities of neurogenic bladder dysfunction in MMC, this review emphasizes the imperative of a collaborative, multidisciplinary approach in urological care, ultimately aiming to enhance patient well-being and functional outcomes.

## Linked entities

- **Chemicals:** oxybutynin (PubChem CID 4634)
- **Diseases:** myelomeningocele (MONDO:0017069)

## Full-text entities

- **Diseases:** urinary tract infections (MESH:D014552), neural tube closure (MESH:D009436), neurogenic bladder dysfunction (MESH:D001750), MMC (MESH:D008591), congenital anomaly (MESH:D000013)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12025530/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12025530/full.md

## References

90 references — full list in the complete paper: https://tomesphere.com/paper/PMC12025530/full.md

---
Source: https://tomesphere.com/paper/PMC12025530